T_Dia
01-14-2010, 09:53 PM
White men with diabetes and prostate cancer had significantly worse outcomes following radical prostatectomy in a new study, and diabetes may further increase the risk for more aggressive disease in obese white men with prostate cancer compared with those without diabetes.
“There is a lot of interest in the role of race, obesity and insulin in prostate cancer, particularly prostate cancer aggressiveness,” Stephen J. Freedland, MD, of the department of surgery and urology at Duke University School of Medicine, told Endocrine Today. “This article highlights first that these interactions may be complex; however, more specifically, it points us in certain directions.”
The retrospective analysis included 1,262 men (47% black; 29% obese) with prostate cancer treated with radical prostatectomy. All were included in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database during 1988 and 2008.
Researchers utilized logistic, proportional hazards and linear regression models to assess the multivariate association between diabetes at surgery and adverse pathology, biochemical recurrence and prostate-specific antigen (PSA) doubling time at recurrence. Data were stratified by race and obesity.
Full Article (http://www.endocrinetoday.com/view.aspx?rid=60004).
“There is a lot of interest in the role of race, obesity and insulin in prostate cancer, particularly prostate cancer aggressiveness,” Stephen J. Freedland, MD, of the department of surgery and urology at Duke University School of Medicine, told Endocrine Today. “This article highlights first that these interactions may be complex; however, more specifically, it points us in certain directions.”
The retrospective analysis included 1,262 men (47% black; 29% obese) with prostate cancer treated with radical prostatectomy. All were included in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database during 1988 and 2008.
Researchers utilized logistic, proportional hazards and linear regression models to assess the multivariate association between diabetes at surgery and adverse pathology, biochemical recurrence and prostate-specific antigen (PSA) doubling time at recurrence. Data were stratified by race and obesity.
Full Article (http://www.endocrinetoday.com/view.aspx?rid=60004).